✕

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Cantor Fitzgerald Reiterates ‘Overweight’ Rating on Elevance Health (ELV)

Cantor Fitzgerald reiterated an ‘Overweight’ rating on Elevance Health, Inc. (NYSE:ELV) on May 29. Additionally, the research firm stuck with the $485 price target. The bullish stance underscores conviction about the company’s earnings potential and prospects for margin expansion.

A healthcare professional in front of a computer monitor analysing the results of a new prognosis prediction test.

The healthcare company has shown resilience, as shown by its 6.63% revenue growth over the past 12 months. According to Sarah James, an analyst at Cantor Fitzgerald, Elevance Health is trading at a discount based on a 12.5 times price-to-earnings multiple of projected 2026 earnings.

Nevertheless, the analyst has reiterated that the company faces various risks. For starters, it is staring at unfavorable outcomes from 2026 Medicare Advantage bids and compression of commercial risks spread. The company could also feel the effects of a shift toward commercial risk from Administrative Services Only (ASO) contracts. Additionally, Elevance Health could feel the impact of a difficult rate environment and irrational pricing strategies by peers in specific markets.

Amid the expected headwinds, Cantor Fitzgerald’s Outperform rating affirms that the company is a favorable investment at its current market valuation. Additionally, it underlines the belief that Elevance Health is well-positioned to navigate the challenges and deliver shareholder value. That’s because Elevance Health reaffirmed its earnings guidance for the whole year, whereby it expects earnings per share to range between $28.30 and $29.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.